Beta Drugs Limited

NSEI:BETA Voorraadrapport

Marktkapitalisatie: ₹20.6b

Beta Drugs Beheer

Beheer criteriumcontroles 4/4

De CEO Beta Drugs is Rahul Batra, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 12.10M, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.41% van de aandelen van het bedrijf, ter waarde ₹ 84.99M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 7.3 jaar.

Belangrijke informatie

Rahul Batra

Algemeen directeur

₹12.1m

Totale compensatie

Percentage CEO-salaris100.0%
Dienstverband CEO3.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur7.3yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Analyse CEO-vergoeding

Hoe is Rahul Batra's beloning veranderd ten opzichte van Beta Drugs's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Compensatie versus markt: De totale vergoeding ($USD 143.26K ) Rahul } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 187.40K ).

Compensatie versus inkomsten: De vergoeding van Rahul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rahul Batra (41 yo)

3.8yrs

Tenure

₹12,100,000

Compensatie

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.2m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mgeen gegevens
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kgeen gegevens
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mgeen gegevens
Seema Chopra
Whole Time Directorno data₹1.19mgeen gegevens
Sanjeev Chopra
Vice President of Technicalno datageen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

40.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BETA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.2m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mgeen gegevens
Seema Chopra
Whole Time Director5.3yrs₹1.19mgeen gegevens
Manmohan Khanna
Independent Director7.3yrsgeen gegevensgeen gegevens
Rohit Parti
Independent Director7.3yrsgeen gegevensgeen gegevens

7.3yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BETA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).